Quercetin and Silymarin loaded Niosomal Formulation with Synergistic Effect on Hep G2 Cell Lines

Abstract

The second most prevalent cancer in the globe and the sixth most frequent cancer overall is liver cancer. More than 90% of liver cancer cases are hepatocellular carcinoma (HCC), which is also the fourth most frequent cancer-related cause of death. Numerous studies have demonstrated that several plants have possible bioactive compounds that may have anti-cancer characteristics to combat cancer and conditions associated with cancer. Plants that contain flavonoids, in particular, aid in the treatment of cancer and cancer-related illnesses. The low solubility of Quercetin, Silymarin in cancer therapy is a critical problem. Niosomes are bi-layered, non-ionic surfactant vesicles that can entrap both hydrophilic and lipophilic drugs in either an aqueous layer or a lipid-based vesicular membrane. Niosomes are extensively researched as a low-cost drug carrier system, biodegradable, biocompatible, safe, and effective. The Ether Injection technique is used to create the Niosome of Quercetin, Silymarin, and a combination of these two medications. In this study, we examine the synergistic effects of Quercetin, Silymarin, and their distinct niosomal formulations on Hep G2 Cell Lines as well as the anticancer (cytotoxic) activity of these medicines individually and in combination. We employ the MTT test to determine the IC50 values for various medications. The findings indicate that the IC50 for quercetin is 50 g, for silymarin is 40 g, and for the combination is 30 g. Comparing the combined effects of these medications to the combined effects of the individual drugs, a considerable increase in cytotoxicity and anti-proliferative impact is seen. In light of these findings, it appears that this mixture has an anti-hyper carcinogenic action that lowers the viable cell count.